KMID : 1039120130020020115
|
|
Clinical and Experimental Vaccine Research 2013 Volume.2 No. 2 p.115 ~ p.119
|
|
Long-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adultsLong-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults
|
|
Song Joon-Young
Cheong Hee-Jin Noh Ji-Yun Yang Tae-Un Seo Yu-Bin Hong Kyung-Wook Kim In-Seon Choi Won-Suk Kim Woo-Joo
|
|
Abstract
|
|
|
Purpose: To prepare for vaccine shortages under an influenza pandemic, several antigen-sparing strategies have been investigated. This study was aimed to evaluate the immunogenicity of influenza vaccine at reduced intradermal and full intramuscular dose.
Materials and Methods: We compared the effect of one-fifth and one-half intradermal doses to the full intramuscular dose on immunogenicity in healthy young adults, using a commercial influenza vaccine. A hemagglutination inhibition assay was used to compare the immunogenicity of the vaccination methods.
Results: The one-fifth intradermal dose (3 ¥ìg hemagglutinin antigen, HA) was given to 30 participants, the one-half intradermal dose (7.5 ¥ìg HA) was given to 30, and the full intramuscular dose (15 ¥ìg HA) was given to 32. No significant differences among injection routes and dosages were seen for seroprotection rate, seroconversion rate, or geometric mean titer (GMT) fold-increase for A/H1N1, A/H3N2, and B at around 4 weeks from vaccination. Although GMT for influenza B was significantly lower at six months for the one-fifth intradermal vaccination compared to the full-dose intramuscular vaccination (32.8 vs. 63.2, p=0.048), all three groups met the Evaluation of Medicinal Products (EMA) immunogenicity criteria through 1 to 6 months.
Conclusion: Intradermal administration of a one-fifth dose of influenza vaccine elicited antibody responses comparable to the intradermal one-half dose and a conventional intramuscular vaccination at 1 month post-vaccination. The immunogenicity of the one-fifth intradermal dose was sufficient to meet the requirement for the EMA criteria at six months after influenza vaccination.
|
|
KEYWORD
|
|
Vaccines, Influenza vaccines, Immunogenicity, Intradermal injections, Adult
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|